Mesalamine Microemulsions for Crohn’s Disease: A Review

Abstract

This analysis delves into the promise of mesalamineencapsulated microemulsions in improving bioavailability and therapeutic effectiveness for Crohn's disease. Crohn’s disease, a persistent inflammatory condition of the bowel, frequently necessitates precise medication administration owing to the particular sites of inflammation found in the gastrointestinal system. Mesalamine, a commonly utilised treatment, exhibits restricted efficacy owing to its inadequate absorption in the upper gastrointestinal tract and swift metabolic breakdown. This manuscript explores the obstacles linked to conventional mesalamine formulations and investigates the latest innovations in microemulsion-driven delivery mechanisms aimed at enhancing drug solubility, stability, and precise targeting. Innovative microemulsion methodologies, such as pH-sensitive and enzymeresponsive frameworks, exhibit potential in overcoming the shortcomings of current therapies, creating opportunities for more efficient and patient-centric treatment alternatives.